Clinical Trial Search

Primary: Percent Reduction Over Placebo for Partial Onset Seizure (Type I) Frequency Over the Treatment Period Standardized to a 28-day Duration — 22.8; 23.2; 0 Percentage of…

Primary: Mean Weekly Log-transformed Seizure Frequency During Weeks 1 Through 10 — 5.20; 10.77 log[seizures per week]

Primary: Percentage Change From Baseline in Seizure Frequency Per Week of Partial Onset Seizures (Type I) During the Up-titration Period — -30.88 percentage of change

Primary: Proportion of Participants With Response to Treatment — 0.59; 0.59 proportion of participants

Primary: The Number of Subjects Completing 24 Weeks Adjunctive Therapy During Maintenance Phase — 36; 37 participants

Primary: Log Transformed (Loge) 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Treatment Phase — 2.24; 2.33; 2.32; 1.84 ln (seizures per 28 days)…

Primary: Mean Change in Focal Interictal Discharges (IEDs) Per Hour, Pre to Post Treatment — -28.8; .54 IEDs/hour — p=>0.05

Primary: Percent Change From Baseline in Partial-onset Seizure Frequency Per 28 Days — 55.6; 21.5 percent seizure reduction — p=<0.0001

Primary: Change in Epworth Sleepiness Scale Score From Baseline to Visit 4 — -1.2; -1.1 Units on a scale — p=0.027

Primary: Functional Connectivity

Primary: 50% Responder Rate After Active rTMS Treatment Compared With Placebo Treatment — 0; 0; 0; 0 participants

Primary: Change From Baseline in Log-Transformed Seizure Frequency During Weeks 8 to 24 of Treatment — -0.43; -0.58 log(seizure/28 days) — p=0.5053

Primary: Percent Change From Baseline in Seizure Frequency Per Week for Partial Onset Seizures (Type I) by Visit and Overall by Period — -26.07; -32.05; -42.22; -31.67 percentage…

Primary: Response Ratio (RRatio) — -24.06; -22.45; -25.90; -24.19 RRatio — p==0.986

Primary: Acute SAE Rate — 12.0 percentage of subjects with ≥ 1 SAE

Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 88.9; 95.5; 100; 94.1 percentage of participants

Primary: Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation…

Primary: The Percentage Change of Monthly Seizure Frequency at the End of the 16-week Treatment From Baseline — -32.7; -35.6 percent change — p=0.240

Primary: Self-reported Seizure Frequency — 6.4 seizure days per 4 weeks

Primary: 58-week Retention Rate Measured by the Number of Drop Outs Due to Adverse Events or Seizures From Day 1 of Treatment — 0.61; 0.46; 0.56 proportion of participants…

Primary: Percentage of Seizure-free Participants (Responders) During Efficacy Assessment Phase — 51.6; 67.9 percentage of participants

Primary: Percent Change From Baseline in Partial-onset Seizure Frequency Per 28 Days — -24.0; -35.5; -55.0; -55.0 percent change — p=<0.001

Primary: Percentage Change From the Combined Baseline in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 28-week Treatment Period (Dose Adjustment + Evaluation…

Primary: Seizure Frequency — 0.655; 0.435; 0.631 Seizures per Day

Primary: Percentage of Participants Remaining on Perampanel Treatment at 3 Months After the Initiation of Treatment — 85.2 percentage of participants

Primary: Safety and Tolerability of Low Frequency Stimulation of the Fornix With Regards to Memory Function — 0; 0 Participants

Primary: Seizure Reduction Rate — -16.35 Percentage of Seizure Reduction Rate

Primary: Percentage of Participants With a Decrease (p<0.05) From Baseline in Threshold Value in Any 5 or More Points in Humphrey 24-2 Swedish Interactive Threshold Algorithm…

Primary: Interictal Epileptiform Discharge (IED) Frequency — 0; 0; 0; 0 IEDs per 5 minutes — p=0.04

Primary: Seizure Frequency